Study
| Global, randomised, open-label, phase 3 trial [DREAMM-7] |
| Relapsed or refractory multiple myeloma after at least one line of therapy |
| Belantamab-Bortezomib-dexamethasone (BVd) (n=243) vs Daratumumab-bortezomib-dexamethasone (n=251) until disease progression or unacceptable toxicity |
Efficacy
| ORR: 83% vs 71% (BVd vs. DVd) |
| MRD-negativity: 25% vs. 10% |
| mDOR: 40.8 mos vs. 17.8 mos |
| mOS: NR vs NR (HR 0.58 [0.43-0.79]) |
| mPFS2: NR vs 33.4 mos (HR 0.59 [0.45-0.77]) |
Safety
| Grade >=3 AEs: thrombocytopenia (56% vs 35%) |
| Serious AEs: pneumonia (12% vs 4%), pyrexia (5% vs 4%), COVID-19 (5% vs 4%) |
| Treatment discontinuations due to AEs: 32% vs 19% |
Lancet Oncol 2025;26:1067–80
http://doi.org/10.1016/S1470-2045(25)00330-4
Reviewed by Elvin Chalabiyev, MD on Sep 3, 2025
